logo

HALEOSLABS vs WINDLAS: Stock Comparison

HALEOS LABS vs WINDLAS BIOTECHUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

WINDLAS BIOTECH is the larger company by market capitalisation. HALEOS LABS shows a lower P/E, while WINDLAS BIOTECH shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

HALEOSLABS leads 4; WINDLAS leads 7 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

HALEOSLABSWINDLAS

Valuation lens

What price are you paying?

Market CapContext only
₹490 Cr
₹1,851 Cr
P/E RatioHALEOSLABS has the lower reading
29.35x ✓
38.76x
P/B RatioHALEOSLABS has the lower reading
2.17x ✓
3.26x
EPSHALEOSLABS has the higher reading
₹8.75 ✓
₹7.58
Book ValueContext only
₹759.29
₹275.2
Dividend YieldWINDLAS has the higher reading
0.09%
0.71% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WINDLAS is the larger company
₹1,851 Cr vs ₹490 Cr
P/E Ratio
HALEOSLABS has a lower P/E
29.35x vs 38.76x
P/B Ratio
HALEOSLABS has a lower P/B
2.17x vs 3.26x
EPS
HALEOSLABS has higher earnings per share
₹8.75 vs ₹7.58
Dividend Yield
WINDLAS has a higher dividend yield
0.71% vs 0.09%
Revenue Growth (TTM YoY)
WINDLAS has faster revenue growth
17.7% vs 0%
EPS Growth (TTM YoY)
HALEOSLABS has faster EPS growth
0% vs -2.6%
ROE
WINDLAS has a higher ROE
11.44% vs 7.75%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHALEOSLABSWINDLAS
Sector—Healthcare
Industry—Pharmaceuticals

Price

MetricHALEOSLABSWINDLAS
Live Price₹1,611.3₹900.4
Day Change1.74%2.17%
Volume89548,867
52-Week High₹1,774₹1,181.9
52-Week Low₹1,181₹697.4
Distance from 52W High-9.17%-23.82%

Valuation

MetricHALEOSLABSWINDLAS
Market Cap₹490 Cr₹1,851 Cr
P/E Ratio29.35x38.76x
P/B Ratio2.17x3.26x
EPS₹8.75₹7.58
Book Value₹759.29₹275.2
Dividend Yield0.09%0.71%

Growth

MetricHALEOSLABSWINDLAS
Revenue Growth (TTM YoY)0%17.7%
EPS Growth (TTM YoY)0%-2.6%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricHALEOSLABSWINDLAS
ROE7.75%11.44%
ROCE6.63%11.95%
Net Margin5.33%7.35%
Operating Margin9.48%10.15%
Debt to Equity0.47x0.05x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricHALEOSLABSWINDLAS
Promoter Holding72.11%63.31%
FII Holding0%2.08%▲ 0.04 pp
DII Holding0.31%7.24%▼ 2.6 pp
Public Holding27.58%27.36%▲ 2.56 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HALEOS LABS and WINDLAS BIOTECH.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.